Developing novel biologics – mAbs & ADCs that target immuno-regulatory receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated mechanisms
The sMIST (SyntheticĀ Microbial Immune Stimulators) platform is based on genetically engineered microbes – “living drugs” that target mutated tumor antigens to induce innate and tumor-specific adaptive immunity
If you are interested in exploring innate immunity and its translation into human therapies, or if your technology could advance the science, please contact us at ir@manhattanbiosolutions.com